Clinical Data Results released at the American Academy of Dermatology (AAD) conference of three Phase 3 studies (UNCOVER-1, UNCOVER-2, UNCOVER-3) of Ixekizumab showed that patients treated with Ixekizumab improved work productivity compared to patients treated with placebo.  In UNCOVER-1 and UNCOVER-2, patients treated with ixekizumab showed significantly greater improvement compared to placebo when evaluated based on absenteeism, presenteeism, work productivity loss and activity impairment.  UNCOVER-3 showed statistically significant improvements compared to placebo in the same areas.